GN introduces its most intelligent hearing portfolio yet, including ReSound Vivia – the world’s smallest AI powered hearing aid
February 4, 2025
ReSound Vivia Built on decades of shared AI research and
Asean
GN introduces its most intelligent hearing portfolio yet, including ReSound Vivia – the world’s smallest AI powered hearing aid
February 4, 2025
ReSound Vivia Built on decades of shared AI research and
GN introduces its most intelligent hearing portfolio yet, including ReSound Vivia – the world’s smallest AI powered hearing aid
February 4, 2025
ReSound Vivia Built on decades of shared AI research and
Beltone Debuts Latest Hearing Innovations with Beltone Envision(TM) Hearing Aids –The World’s Best Technology for Hearing in Noise And New Auracast Assistant
February 4, 2025
Designed with intelligent hearing technology, Beltone Envision AI powered hearing
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
October 21, 2024
The agreement gives Angelini Pharma an option to exclusive licensing
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
October 21, 2024
The agreement gives Angelini Pharma an option to exclusive licensing
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
October 21, 2024
The agreement gives Angelini Pharma an option to exclusive licensing
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
October 1, 2024
Collaboration to include the clinical development, regulatory filing, and commercialization
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
October 1, 2024
Collaboration to include the clinical development, regulatory filing, and commercialization
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
October 1, 2024
Collaboration to include the clinical development, regulatory filing, and commercialization